FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

→ The FDA has green-light­ed Merz North Amer­i­ca’s sup­ple­men­tal Bi­o­log­ics Li­cense Ap­pli­ca­tion (sBLA) for Xeomin for the treat­ment of ex­ces­sive drool­ing (chron­ic sial­or­rhea) in adult pa­tients. Drool­ing is a com­mon symp­tom among pa­tients who suf­fer from neu­ro­log­i­cal dis­or­ders in­clud­ing Parkin­son’s dis­ease, ALS, cere­bral pal­sy and stroke. Merz says Xeomin is the first and on­ly neu­ro­tox­in with this ap­proved in­di­ca­tion in the US. This is the fourth neu­ro­log­i­cal in­di­ca­tion for Xeomin, which was first ap­proved by the FDA in 2010.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.